COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

ITA-HEMA-COV Investigators, F. Passamonti, A. Romano, M. Salvini, F. Merli, M.G.D. Porta, R. Bruna, E. Coviello, I. Romano, R. Cairoli, R. Lemoli, F. Farina, A. Venditti, A. Busca, M. Ladetto, M. Massaia, A. Pinto, L. Arcaini, A. Tafuri, F. MarchesiN. Fracchiolla, M. Bocchia, D. Armiento, A. Candoni, M. Krampera, M. Luppi, V. Cardinali, S. Galimberti, C. Cattaneo, E.O. La Barbera, R. Mina, F. Lanza, G. Visani, P. Musto, L. Petrucci, F. Zaja, P.A. Grossi, L. Bertù, L. Pagano, P. Corradini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)371-377
JournalBritish Journal of Haematology
Volume195
Issue number3
DOIs
Publication statusPublished - 2021

Keywords

  • Covid-19
  • leukemia
  • lymphoma
  • myeloma
  • SARS-CoV-2

Cite this